Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001567619-22-011720
Filing Date
2022-05-25
Accepted
2022-05-25 19:02:11
Documents
1
Period of Report
2022-05-23

Document Format Files

Seq Description Document Type Size
1 FORM 4 doc1.html 4  
1 FORM 4 doc1.xml 4 4430
  Complete submission text file 0001567619-22-011720.txt   6025
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Issuer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 10 HUDSON YARDS, 37TH FL NEW YORK NY 10001
Business Address
Miller-Rich Nancy (Reporting) CIK: 0001735084 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39782 | Film No.: 22964521